Home › Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302
 

Keywords :   


Therapure Innovations Receives FDA Approval To Proceed With A Phase 1 Clinical Trial Of The Targeted Liver Cancer Therapeutic TBI 302

2015-04-01 08:23:10| drugdiscoveryonline Home Page

Therapure Innovations, a division of Therapure Biopharma Inc., recently announces that the U.S. Food and Drug Administration (FDA) has given the company approval to proceed with a Phase 1 clinical trial of TBI 302, a targeted therapeutic for the treatment of liver cancer

Tags: trial phase approval cancer

Category:Biotechnology and Pharmaceuticals

Latest from this category

All news
»
16.05'Time running out' plea over shipyard's future
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05China's Nio unveils Tesla Model Y rival
16.05Could the US economy be doing too well?
16.05Eastern North Pacific Tropical Weather Outlook
16.05Atlantic Tropical Weather Outlook
16.05The man who turned his dead father into a chatbot
More »